
11 Jan 2019 Research
Myelofibrosis: Finding new ways to treat patients
Myelofibrosis is a fatal bone marrow cancer. The disease is caused by excessive secretion of factors by cancerous platelet-producing cells called megakaryocytes. These secretions cause the replacement of normal bone marrow tissue with fibrous scar tissue.
Dr Chen’s team can successfully recreate this pathological bone marrow environment in the laboratory, and their preliminary research data shows that reduced levels of a protein complex called FANCcore leads to more myelofibrosis.
Dr Chen’s team hypothesise that loss of the protein complex FANCcore increases the growth of myelfibrosis by altering megakaryocytes. Dr Chen uses both human tissue cultures and mouse models to examine the cellular and molecular changes to megakaryocytes following the absence of the FANCcore complex and to understand how these changes cause myelofibrosis.
The team hopes that by focusing on the role of FANCcore in megakaryocyte biology, they can reveal new ways to treat myelofibrosis.
11 January 2019
Leukaemia UK and Leuka have merged
We are delighted to announce that on 1 November Leuka and Leukaemia UK merged
23 September 2022
Spectacular sailing challenge in memory of Pat Buckley
Royal Corinthian Yacht Club’s 61st Endeavour Trophy fundraiser for Leukaemia UK A fleet of thirty boats displaying the Leukaemia UK logo on their sails will put on a spectacular racing…
3 July 2025
Together we are changing lives – Here’s how your support is making it happen
At this point in our advocacy journey, we wanted to share an update to you, our supporters, on everything we’ve achieved so far and what’s next as we continue to…
10 August 2022
Leukaemia UK unveils an exciting new brand
Leukaemia UK has today revealed a bold new look and feel that embodies the charity’s ambitious new strategy and our desire to be a greater force for change. Bringing together…